tirabrutinib hydrochloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitors | 5423 | 1351636-18-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Tirabrutinib is a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly and covalently binds to BTK Cys-481 in B cells and inhibits aberrant B cell receptor signalling in B cell-related cancers and autoimmune diseases.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 25, 2020 | PMDA | Ono Pharmaceutical |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Malignant lymphoma | indication | 118600007 | DOID:0060058 |
| Waldenström macroglobulinemia | indication | 190818004 | DOID:0050747 |
| Primary central nervous system lymphoma | indication | 307649006 | DOID:3234 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase BTK | Kinase | INHIBITOR | IC50 | 8.17 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | Kd | 6.21 | CHEMBL | |||||
| Platelet glycoprotein VI | Unclassified | IC50 | 5.92 | CHEMBL | |||||
| Receptor tyrosine-protein kinase erbB-4 | Kinase | INHIBITOR | IC50 | 7.11 | SCIENTIFIC LITERATURE | ||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 6.43 | CHEMBL | |||||
| Tyrosine-protein kinase Tec | Kinase | INHIBITOR | IC50 | 7.32 | SCIENTIFIC LITERATURE | ||||
| Tyrosine-protein kinase TXK | Kinase | INHIBITOR | IC50 | 7.04 | SCIENTIFIC LITERATURE | ||||
| Tyrosine-protein kinase Blk | Kinase | INHIBITOR | IC50 | 6.52 | SCIENTIFIC LITERATURE | ||||
| Cytoplasmic tyrosine-protein kinase BMX | Kinase | INHIBITOR | IC50 | 8.22 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D11070 | KEGG_DRUG |
| U374135N48 | UNII |
| C4683808 | UMLSCUI |
| 71571562 | PUBCHEM_CID |
| CHEMBL4071161 | ChEMBL_ID |
| C000608238 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9265 | IUPHAR_LIGAND_ID |
| DB15227 | DRUGBANK_ID |
| 10320 | INN_ID |
| 1439901-97-9 | SECONDARY_CAS_RN |
Pharmaceutical products:
None